GleamWall
中文EN

CPMV Mosaic ImmunoEngineering Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 836564 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY0.8%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-2,254.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets238,930.6%
Debt / equity—
Current ratio0.00x
Interest coverage-60.40x

Cash quality & payout

Operating cash flow / net income0.08x
Accruals ratio-2,078.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue————————
R&D expense$15,608$15,880$16,133$16,039$16,006$15,803$16,250$39,599
SG&A expense$141,113$138,922$132,000$128,319$132,848$158,971$133,907$146,831
Operating income-$156,721-$154,802-$148,133-$144,358-$148,854-$174,774-$150,157-$186,430
Interest expense$2,492$2,467$2,521$2,521$2,493$2,466$3,004$2,817
Pretax income-$177,496-$175,351-$169,137-$165,361-$169,628-$181,320-$150,644-$186,730
Income tax$0$0$0$0$2,400$0$2,400$0
Net income-$177,496-$175,351-$169,137-$165,361-$172,028-$181,320-$153,044-$186,730
EPS (basic)-0.02-0.02—-0.02-0.02-0.03—-0.03
EPS (diluted)-0.02-0.02—-0.02-0.02-0.03—-0.03
Weighted avg. shares (diluted)7.24M7.24M—7.24M7.24M7.24M—7.24M
Balance sheet
Cash & equivalents$26$72$3,622$31,761$53,583$85,930$115,019$5,736
Current assets$3,278$9,828$19,882$55,298$57,699$97,784$141,611$39,950
Total assets$3,278$9,828$19,882$55,298$57,699$97,784$141,611$39,950
Current liabilities$6.33M$6.18M$6.03M$5.91M$5.77M$5.66M$5.54M$5.30M
Total liabilities$7.83M$7.66M$7.50M$7.36M$7.20M$7.07M$6.93M$6.68M
Shareholders' equity-$7.83M-$7.65M-$7.48M-$7.31M-$7.14M-$6.97M-$6.79M-$6.64M
Shares outstanding7.24M7.24M7.24M7.24M7.24M7.24M7.24M7.24M
Cash flow statement
Operating cash flow-$46-$3,550-$28,139-$21,822-$32,347-$29,089-$20,717-$12,998
Investing cash flow——————$0$0
Financing cash flow——$0$0——$130,000$15,000
Stock-based compensation$0$0$0$0$0$0$0$0

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.